Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was ...

The eye-care company Alcon Research has entered into licensing and purchase option agreements with Potentia Pharmaceuticals to develop Potentia's leading drug candidate — a complement pathway ...

Mannan-binding lectin (MBL), M-, L- and H-ficolin recognize microorganisms and activate the complement system via MBL-associated serine proteases (MASPs). We investigated lectin pathway cord blood ...

The complement system comprises 30 proteins that are involved in the classical, alternate, and lectin pathways, all of which converge in C3 cleavage, a major complement component. Complement ...

H.C. Wainwright reiterates a Buy rating and $80 price target on shares of Arrowhead (ARWR) Pharmaceuticals after the company announced top-line ...